SEC Stock Data Quick Answer Allarity Therapeutics, Inc. reported Stockholders Equity of $9.83 million for fiscal year 2025. Allarity Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $9.83M -16.8% 2024 $11.81M +529.3% 2023 -$2.75M -2334.5% 2022 -$113.0K -100.6% 2021 $18.15M -25.7% 2020 $24.44M +22.0% 2019 $20.04M — Quarterly Stockholders Equity Quarter Ending … Read more
Quick Answer Allarity Therapeutics, Inc. reported Cash and Equivalents of $14.69 million for fiscal year 2025. Allarity Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $14.69M -24.8% 2024 $19.53M +11666.9% 2023 $166.0K -91.8% 2022 $2.03M — Quarterly Cash and Equivalents Quarter Ending Cash and Equivalents YoY QoQ … Read more
Quick Answer Allarity Therapeutics, Inc. reported Total Assets of $18.26 million for fiscal year 2025. Allarity Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $18.26M -19.4% 2024 $22.65M +90.9% 2023 $11.86M -18.4% 2022 $14.54M -70.7% 2021 $49.63M +48.6% 2020 $33.40M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer Allarity Therapeutics, Inc. reported Diluted EPS of $10.26 per share (loss) for fiscal year 2023. Allarity Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2023 -$10.26 +99.7% 2022 -$3093.42 -73728.6% 2021 -$4.19 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ June 30, 2024 -$0.11 +100.0% +99.5% … Read more
Quick Answer Allarity Therapeutics, Inc. reported Net Income of -$11.23 million for fiscal year 2025. Allarity Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$11.23M +54.2% 2024 -$24.52M -106.0% 2023 -$11.90M +25.9% 2022 -$16.06M +39.7% 2021 -$26.65M -302.7% 2020 -$6.62M — Quarterly Net Income Quarter Ending Net Income YoY … Read more
Quick Answer Allarity Therapeutics, Inc. reported Net Income of -$11.23 million for fiscal year 2025. Allarity Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income -$11.23M+54.2% -$24.52M-106.0% -$11.90M+25.9% -$16.06M+39.7% -$26.65M-302.7% -$6.62M Diluted EPS — — -$10.26+99.7% -$3093.42-73728.6% -$4.19 — Total Assets $18.26M-19.4% $22.65M+90.9% $11.86M-18.4% $14.54M-70.7% $49.63M+48.6% $33.40M Cash … Read more
Quick Answer Allogene Therapeutics, Inc. reported Shares Outstanding of 229.41 million shares for fiscal year 2025. Allogene Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 229.41M +8.1% 2024 212.21M +25.8% 2023 168.64M +0.3% 2023 168.18M +0.6% 2023 167.13M +14.7% 2023 145.74M +0.9% 2022 144.44M +0.3% 2022 144.03M +0.2% 2022 … Read more
Quick Answer Allogene Therapeutics, Inc. reported Operating Income of -$209.31 million for fiscal year 2025. Allogene Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$209.31M +23.4% 2024 -$273.20M +16.6% 2023 -$327.74M +2.3% 2022 -$335.54M -86.2% 2021 -$180.19M +30.2% 2020 -$258.24M -27.8% 2019 -$202.01M -4.8% 2018 -$192.84M -9642000.0% 2017 -$2.0K … Read more
Quick Answer Allogene Therapeutics, Inc. reported R&D Expense of $150.15 million for fiscal year 2025. Allogene Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $150.15M -21.9% 2024 $192.30M -20.8% 2023 $242.91M -5.3% 2022 $256.39M +16.4% 2021 $220.18M +14.1% 2020 $192.99M +33.5% 2019 $144.53M -4.8% 2018 $151.86M — 2017 $0.00 … Read more
Quick Answer Allogene Therapeutics, Inc. reported Stockholders Equity of $292.54 million for fiscal year 2025. Allogene Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $292.54M -30.7% 2024 $422.18M -17.6% 2023 $512.23M -11.8% 2023 $580.63M -6.6% 2023 $621.41M +5.0% 2023 $592.01M -11.2% 2022 $666.88M -10.3% 2022 $743.40M -7.8% 2022 $806.48M … Read more